TL;DR
This study provides crucial real-world data on the outcomes of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), particularly in the second-line setting. It highlights a short median progression-free survival (PFS) of 4.6 months for patients treated with docetaxel-based regimens, underscoring the need for more effective therapies in this challenging patient population.
What Problem Does This Paper Address?
For years, KRAS mutations, particularly KRAS G12C, were considered "undruggable" targets in non-small cell lung cancer (NSCLC). While the FDA approved sotorasib in 2021 as the first targeted therapy for this patient group, much of the initial data came from single-arm studies, often in later lines of treatment. There was a significant gap in understanding the real-world clinical outcomes for patients with KRAS G12C-mutated NSCLC, especially in the second-line setting, where treatment options were limited and less well-characterized. This paper aims to fill that gap by compiling a large, multi-center historical dataset to clarify these outcomes.
Methods
This study employed a multicenter retrospective chart review. Data was collected from 13 academic medical centers across the United States and Canada. The researchers analyzed the clinical characteristics and outcomes of 396 patients diagnosed with stage IV or recurrent, metastatic KRAS G12C-mutated NSCLC between 2006 and 2020. The primary outcomes of interest were real-world progression-free survival (rwPFS) and overall survival (OS) from the time of stage IV or metastatic diagnosis. A particular focus was placed on patients treated with second-line docetaxel-containing regimens and the impact of co-occurring STK11 or KEAP1 mutations.
Datasets
The study utilized a dataset of 396 patients with KRAS G12C-mutated NSCLC, collected retrospectively from 13 academic medical centers. This dataset represents real-world clinical practice and differs from controlled trial data by encompassing a broader range of patient characteristics and treatment variations.
Key Insights and Ideas
- Docetaxel's Limited Efficacy in Second-Line: The most striking finding is the short median rwPFS of 4.6 months for the small subset of patients treated with docetaxel (with or without ramucirumab) in the second-line setting. This highlights a significant unmet need for more effective therapies in this specific scenario.
- Co-occurring Mutations Matter: Patients with KRAS G12C and STK11 co-mutations showed inferior outcomes, with a shorter median rwPFS on first-line therapy (6.0 months) compared to those without this co-mutation. This reinforces the importance of comprehensive molecular profiling.
- Real-World Data is Crucial: The study emphasizes the value of real-world data in complementing clinical trial findings, especially for a relatively new targeted therapy landscape.
Key Results
- Among 201 patients with KRAS G12C-mutated NSCLC who received first-line systemic therapy, the median first-line rwPFS was 9.3 months and median OS was 16.8 months.
- In the second-line setting, among 123 patients with documented therapy, the median rwPFS was 8.3 months.
- Crucially, for the 10 patients treated with docetaxel (with or without ramucirumab) in the second-line, the median rwPFS was a mere 4.6 months.
- Approximately 12% of the study population had a co-occurring STK11 mutation, and 3% had a KEAP1 mutation.
- For the 23 patients with KRAS G12C and STK11 co-mutations on first-line therapy, the median rwPFS was 6.0 months, and median OS was 14.0 months.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Nature: The study design inherently carries limitations related to data completeness and potential biases.
- Potential Immortal Time Bias: The OS estimate for brain metastases might be affected by immortal time bias.
- Limited Docetaxel Cohort: The small number of patients treated with docetaxel in the second-line limits the generalizability of those specific findings.
- Evolving Standard of Care: The treatment interval spanned a period where first-line therapy for NSCLC evolved, particularly with the rise of chemoimmunotherapy, which may affect the interpretation of older data.
Future work should focus on prospective studies to evaluate novel therapies in the second-line setting for KRAS G12C-mutated NSCLC, especially for patients with co-occurring mutations. Further research into the mechanisms driving resistance to current therapies and the development of combination strategies is also warranted.
Summary updated